Table 2.
LncRNAs | Epigenetic Mechanism | Expression in BC | Target Gene or Protein/Pathway Involved | Biological Function | Ref. |
---|---|---|---|---|---|
LncRNA APOC1P1-3 | Regulation of lncRNA expression by DNA methylation | ↑ | APOC1P1-3/α-tubulin acetylation | Inhibiting apoptosis | [75] |
LncRNA EPIC1 | ↑ | LncRNA EPIC1/MYC | Promoting Cell-Cycle progression | [76] | |
LncRNA HUMT | ↑ | HUMT/YBX1/FOXK1 axis | Promoting lymphangiogenesis and metastasis | [77] | |
LncRNA GAS5 | ↓ | Not applicable | Promoting chemosensitivity and apoptosis | [78] | |
LncRNA MEG3 | ↓ | Not applicable | Promoting chemosensitivity | [79] | |
LncRNA MYMA | Regulation of DNA methylation by lncRNA | ↑ | ROR1/HER3/lncRNA MYMA axis | Promoting bone metastasis | [80] |
LncRNA 91H | ↑ | LncRNA 91H -H19/IGF2 | Increasing aggressive phenotype | [81] | |
LncRNA PYCARD-AS1 | Not applicable | LncRNA PYCARD-AS1/PYCARD | Regulating apoptosis | [82] | |
LINC00518 | ↑ | LINC00518/CDX2/Wnt signaling | Promoting epithelial cell growth and metastasis | [83] | |
LncRNA H19 | ↑ | H19/SAHH/DNMT3B axis | Promoting tamoxifen resistance | [84] | |
LncRNA BCLIN25 | ↑ | BCLIN25/miR-125b/ERBB2 axis | Promoting tumorigenesis | [85] | |
LncRNA MIAT | ↑ | LncRNA MIAT/DLG3/Hippo signaling pathway | Promoting tumorigenesis | [86] | |
LINC00472 | ↓ | LINC00472/MCM6/MEK/ERK signaling pathway | Inhibiting metastasis | [87] | |
LncRNA TINCR | ↑ | STAT3/TINCR/EGFR feedback loop | Promoting tumorigenesis | [88] | |
LncRNA LINC00922 | ↑ | LINC00922/NKD2/Wnt signaling pathway | Promoting EMT, invasive and migratory capacities | [89] | |
LncRNA MAGI2-AS3 | ↓ | MAGI2-AS3/MAGI2/Wnt/β-catenin pathway | Inhibiting cell proliferation and migration | [90] | |
LncRNA SNHG10 | ↓ | LncRNA SNHG10/miR-302b | Promoting chemosensitivity of TNBC cells to doxorubicin. | [91] | |
LNC942 | Regulation of m6A modification by lncRNA | ↑ | LNC942/METTL14/CXCR4 and CYP1B1 signaling axis | Promoting proliferation and inhibiting apoptosis | [92] |
LINC00675 | M6A modification of lncRNA | ↓ | METTL3/LINC00675/miR-513b-5p | Suppressing proliferation, migration, and invasion | [93] |
LncRNA DLEU1 | Regulation of lncRNA expression by histone methylation | ↑ | Not applicable | Promoting tumorigenesis | [94] |
LncRNA EPB41L4A-AS2 | ↓ | ZNF217/EPB41L4A-AS2/RARRES1 | Inhibiting proliferation, migration, and invasion and inducing apoptosis | [95] | |
LncRNA HOTAIR | ↑ | Not applicable | Associating with endocrine disruption | [96] | |
LncRNA UCA1 | Not applicable | SATB1/lncRNA UCA1 | Promoting growth and metastasis | [97] | |
LncRNA HOTAIR | Regulation of histone methylation by lncRNA | ↑ | Not applicable | Promoting invasiveness and metastasis | [98] |
LncRNA UCA1 | ↑ | LncRNA UCA1/EZH2/p21 axis | Inducing tamoxifen resistance | [99] | |
LINC00511 | ↑ | LINC00511/EZH2/CDKN1B | Promoting proliferation and inhibiting apoptosis | [100] | |
LncRNA ROR | ↑ | LncRNA ROR/MLL1/TIMP3 | Promoting BC progression | [101] | |
LncRNA PHACTR2-AS1 | ↓ | EZH2/lncRNA PHACTR2-AS1 | Inhibiting growth and metastasis | [102] |
EMT, epithelial–mesenchymal transition. ↓, down-regulation in BC. ↑, up-regulation in BC.